Navigation Links
New Study Published in Journal of Drugs in Dermatology Finds Artefill Effective in Treating Atrophic Acne Scars
Date:10/7/2010

SAN DIEGO, Oct. 7 /PRNewswire/ -- Suneva Medical, a privately-held aesthetic medical device company, today announced the publication of an open-label, single center, pilot study on Artefill® for the treatment of atrophic acne scars conducted by James M. Spencer, M.D. M.S. and sponsored by Suneva Medical. The article, which appears in the September 2010 issue of Journal of Drugs in Dermatology, shows Artefill to have a significant and lasting effect on patient atrophic acne scars after an eight month period.

The study consisted of fourteen (n=14) healthy male and female patients between the ages of 18 and 60 who met all inclusion and exclusion criteria and had atrophic acne scars amenable to correction with Artefill.  Patients were evaluated at six weeks and eight months after the initial injection. The investigators concluded that 96 percent of the treated acne scars noticeably improved and 70 percent improved by two grades. Patients reported being highly satisfied with Artefill with the vast majority or 93 percent willing to have a repeat procedure. No adverse events or side effects were evident over the course of the study.

Dr. Spencer, lead study investigator commented, "Our patients saw an outstanding correction with Artefill and we believe it will provide them long lasting and possibly permanent results.  We will continue to follow these patients over a three-year period but the data indicates Artefill is safe and effective for these challenging scars."

Acne is a disorder that effects up to 80 percent of individuals between 11 and 30 years of age and up to 5 percent of older adults. Atrophic acne scars result when there is a loss of tissue and will create a pitted or pockmarked look of the skin. While not all patients will develop acne scars, when they do occur ninety-five percent are on the face, potentially affecting a patient's self-confi
'/>"/>

SOURCE Suneva Medical
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... -- In accordance with Rule 17.1 and Rule 2.9 of ... States Exchange Act, Echo Pharma Acquisition Limited ("Royalty Pharma") today ... ELN). Background On 2 May 2013, ... the entire of the issued and to be issued share ... On 20 May 2013, Royalty Pharma announced the ...
(Date:5/23/2013)... -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ) today ... Science Firm of the Year by the Tech Council of ... the TCM,s 25 th Annual Tech Awards Celebration held ... Celebration recognizes the leaders and innovators in the technology and ... the surrounding regions. "We are deeply honored ...
(Date:5/23/2013)... RIVER EDGE, N.J. , May 23, 2013 /PRNewswire/ ... ), a commercial stage medical device company that develops ... the successful completion of its rights offering.  In addition, ... company,s March 2011 warrants expired on May 17, 2013. ... proceeds of $3.0 million from the rights offering.   A ...
Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
... and ATLANTA , March 15 ... announced results from an analysis of one-year subset data ... diabetes on clinical and angiographic outcomes in heart attack ... Stent System or the Express® bare-metal stent.  The results ...
... Watson Pharmaceuticals, Inc. (NYSE: WPI ... – Florida , has received approval from the ... New Drug Application (ANDA) for Diltiazem Hydrochloride Extended-Release tablets, ... LA product.  Watson intends to launch its generic version ...
Cached Medicine Technology:Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 2Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 3Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 4Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 5Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 6Watson Receives FDA Approval for Generic Cardizem(R) LA 2Watson Receives FDA Approval for Generic Cardizem(R) LA 3
(Date:5/24/2013)... KC and Monica Craichy, Founders of Living Fuel, Inc ... Kyle and Austin Craichy, will be kiteboarding with members of ... , KC Craichy said he is excited to be involved ... that virtually everyone who planned to be involved is going ... meet at Matheson Hammock Park and Beach in Miami at ...
(Date:5/24/2013)... Mirena IUD lawyers at the Rottenstein Law Group ... more than 59,229 complaints since 2004 from women claiming they ... known as the Mirena IUD.* , Among the most common ... ‘expulsion,’ where the IUD came out on its own. There ... News article. “Abdominal pain is also common, with 3,774 complaints. ...
(Date:5/24/2013)... 2013 E-Dentists.com has announced the launch ... JD Media Surge, a leading medical Internet marketing agency. ... analysis service will focus on providing dentists the help ... for their competitive keywords. The dental SEO analysis covers ... based on what their competitors are doing right. The ...
(Date:5/24/2013)... OR (PRWEB) May 24, 2013 ... Sustainable Cards, major competitors in sustainable card material, ... of using forest materials as a sustainable gift ... is to identify industry challenges and increase education ... card programs to support the reduction of carbon ...
(Date:5/24/2013)... May 24, 2013 Started in 1982, AMTC’s ... in Orlando. 2013 marks AMTC’s 31st anniversary. SHINE is a ... with supermodel Millie Lewis and her daughter, Carey Lewis Arban. ... managers, casting directors, and music professionals including the New York ... XP Media. They are kings of Hollywood and Christian casting ...
Breaking Medicine News(10 mins):Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3Health News:Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes 2Health News:Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 3Health News:AMTC’s Summer SHINE Event Coming to Orlando’s Luxurious Gaylord Palms July 2-7, 2013 2
... Japan to colloborate in marketing of Merck's cancer drug ... is in its Phase II // clinical tiral. ... royalty and sale benefits from the sale of Matuzumba. ... an addition of royalty., ,"Merck KGaA and Takeda ...
... (PET) brain scans may help in planning surgery to ... study presented at the 130th annual meeting of the ... from National Institutes of Neurological Disorders and Stroke had ... deficits in signaling for the neurotransmitter serotonin is more ...
... getting hospitals conscious about quality of services offered can reduce ... percent fewer patients died in the first year after their ... prevent crucial heart-care steps in much the same way a ... it leaves the factory., ,The steps included a checklist ...
... standards and strict hygienic conditions has to be monitored ... of hospital care and increase in number of hospitals ... should me monitored for the benefit of the ... facilities in Indian hospitals, there is an increase in ...
... Dr Reddy's Laboratories Thursday announced it had entered a ... the joint development of a drug to treat diabetes. ... fund all costs associated with the Phase-III clinical trials ... the treatment of type 2 diabetes., ,Dr Reddy's ...
... made by researchers at Wake Forest University School of Medicine said ... are quite high and it is also linked to the emphasis ... rates of musculoskeletal injuries. Almost half of workers reported pain in ... five of those workers was unable to work for at least ...
Cached Medicine News:Health News:Dr Reddy’s Strikes Deal With Rheoscience For Type 2 Diabetes Dru 2Health News:Injury Rates High For Workers In Poultry Farms 2
... stereotactic, ultrasound and MRI-guided vacuum assisted breast ... Use the patented, FDA-cleared ATEC system for ... advanced method of breast biopsy. Its compassionate ... who trust YOU.,9 Gauge Handpieces: Useful for ...
... stereotactic, ultrasound and MRI-guided vacuum assisted breast ... Use the patented, FDA-cleared ATEC system for ... advanced method of breast biopsy. Its compassionate ... who trust YOU.,9 Gauge Handpieces: Useful for ...
Three-spring evacuator kits with silicone drains, 10 in. hole pattern, trocar and Y-connector tubing...
Provides reliable suction for surgical cases with larger amounts of drainage....
Medicine Products: